Associate Professor of Medicine, Dana-Farber Cancer Institute
Oncology
Dr. Frank S. Hodi Jr., MD
|
|
Give Review
Frank Hodi is an expert in the field of Oncology. He attended Weill Cornell Medical College of Cornell University. Weill Cornell Medical College of Cornell University is ranked 18/49 in Research/PrimaryCare. He received awards:"Regional Top Doctor" and "Elected Member". Frank Hodi is also published. He has 40 publications published. The lastest publication: "Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab.' Frank Hodi is registered with Medicare.
Publications
- Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva.
- A Systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab.
- PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells.
- Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy.
- CCR 20th Anniversary Commentary: Immune-Related Response Criteria-Capturing Clinical Activity in Immuno-Oncology.
- Phase 2 study of sunitinib in patients with metastatic mucosal or acral Melanoma.
- Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study.
- Immunity to the vacuolar ATPase complex accessory unit ATP6S1 in patients with malignant Melanoma.
- Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic Melanoma: a randomized clinical trial.
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in Cancer patients.
- Durable benefit and the potential for long-term survival with immunotherapy in advanced Melanoma.
- Clinical utility of a blood-based BRAF V600E mutation assay in Melanoma.
- PD-L1 Expression in Non-clear Cell Renal Cell Carcinoma.
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced Melanoma: a randomised dose-comparison cohort of a phase 1 trial.
- Melanoma, version 4.2014.
- Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade.
- Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma.
- Pretreatment serum VEGF is associated with clinical response and overall survival in advanced Melanoma patients treated with ipilimumab.
- Outcomes of patients with metastatic Melanoma treated with immunotherapy prior to or after BRAF inhibitors.
- Anti-PD1 Following Ipilimumab for Mucosal Melanoma: Durable Tumor Response Associated with Severe Hypothyroidism and Rhabdomyolysis.
- Reversal of in situ T Cell exhaustion during effective human anti-leukemia responses to donor lymphocyte infusion.
- CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients.
- Challenges relating to solid tumour Brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group.
- Challenges relating to solid tumour Brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group.
- Clinical activity of ipilimumab for metastatic uveal melanoma: A retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Slo...
- Ipilimumab, Vemurafenib, Dabrafenib, and Trametinib: Synergistic Competitors in the Clinical Management of BRAF Mutant Malignant Melanoma.
- Activity of the heat shock protein 90 inhibitor ganetespib in Melanoma.
- BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma.
- Protein Kinase C Inhibitor AEB071 Targets Ocular Melanoma Harboring GNAQ Mutations via Effects on the PKC/Erk1/2 and PKC/NF-κB Pathways.
- From genes to drugs: targeted strategies for Melanoma.
- c-Met, epidermal growth factor receptor, and insulin-like growth factor-1 receptor are important for growth in uveal Melanoma and independently contribute to migration...
- Programmed death ligand-1 expression in adrenocortical Carcinoma: an exploratory biomarker study.
- Response assessment in metastatic Melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome.
- Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in Melanoma patients treated with ipilimumab?
- A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic Melanoma in the United States.
- Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab.
- Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model.
- Melanoma in 2015: Immune-checkpoint blockade - durable Cancer control.
- STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-Cell Activity in the Lung Tumor Microenvironment.
Schools
Joan Sanford I Weill Medical College Of Cornell University
University Hospital Penn
Brigham and Womens Hospital
University Of Pennsylvania Health System
Dana Farber Cancer Institute
Harvard Med School
Conditions Treated
- Adrenal Gland Cancer
- Anemia
- Basal Cell Carcinoma
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Regional Top Doctor
- Elected Member
Education
-
Brigham and Women's Hospital -
University of Pennsylvania Health System -
Weill Cornell Medical College of Cornell University
Hospital
-
Brigham and Women's Hospital -
Massachusetts General Hospital -
Dana-Farber Cancer Institute
Helpful Reviews
Similar Doctors
|
|
Dr. Elizabeth B. Lamont, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Christine Legler
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michaela J. Higgins, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Diane M. Savarese, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Donald W. Kufe, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Michael Hassett, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alexi A. Wright, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jason Luke, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Edwin Choy, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Thomas A. Abrams, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lee M. Nadler, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Gretchen A. Gignac, MD
This Doctor is OpenDoctor Recommended.
|